HydRegen is a 2021 spin-out from the University of Oxford developing enzyme-based biocatalyst systems that replace toxic heavy-metal catalysts in industrial hydrogenation and reductive amination, serving pharmaceutical and fine-chemical manufacturers. Led by CEO Dr Holly Reeve, its Bio2Amine technology and continuous-flow hydrogenation hardware let chemical producers cut cost, energy use and carbon footprint in existing plant processes. Backers include Clean Growth Fund and UK Innovation & Science Seed Fund, and the team has won recognition including a Royal Society of Chemistry Horizon Prize.
1
Round
1
Industry
5
Tags
Oct 14, 2026
Latest raise
Funding activity · 1 round
Oct 14, 2026
$8M
Series A
Led by Genoa Ventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
